ArticleFrontiers in microbiology2025
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Extracellular polysaccharide capsules of Gram-negative bacteria, such as Methods: In this study, we examined the Group 2 K2 capsule of the extra-intestinal pathogenic Results: The K2 capsule of CFT073 exhibited dual functionality, acting both as a barrier to phage infection and as a receptor facilitating infection. A previously unrecognized synergy was observed between capsule expression and a type IV toxin-antitoxin (TA) system in CFT073. It was also shown that co-localisation of capsule and TA loci was present in more than 500 Discussion: These findings highlight the complex role of capsules in phage interactions and suggest that their functional linkage with TA systems may enhance bacterial persistence. The conserved co-acquisition of these loci on pathogenicity islands underscores their potential importance in the evolution and success of ExPEC pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.